首页> 外国专利> Method to diagnose the presence and / or severity of a liver pathology in a subject and / or to control the effectiveness of the treatment of said pathology

Method to diagnose the presence and / or severity of a liver pathology in a subject and / or to control the effectiveness of the treatment of said pathology

机译：诊断受试者中肝脏病理的存在和/或严重性和/或控制所述病理的有效性的方法

页面导航

摘要
著录项
相似文献

摘要

Method for diagnosing the presence and / or severity of a liver pathology, in particular a liver fibrosis in a subject comprising the establishment of at least one non-invasive diagnostic score of portal and septal fibrosis by performing the following stages: a ) measuring in a sample of said subject three, four, five, six or seven variables chosen in the group consisting of α-2 macroglobulin (A2M), hyaluronic acid (AH or hyaluronate), apoliprotein Al (ApoAl), N-terminal propeptide of type III procollagen (P3P), gamma-glutamyltranspeptidase (GGT), bilirubin, gamma globulins (GLB), platelets (PLQ), prothrombin rate (TP), aspartate amino transferase (ASAT), alanine amino transferase (ALAT ), urea, sodium (NA), glycemia, triglycerides, albumin (ALB), alkaline phosphatases (PAL), YKL-40 (human cartilage glycoprotein 39), Tissue matrix 1 metalloproteinase inhibitor (TIMP-1), metalloproteinase of matrix 2 (MMP-2), Ferritin, one of at least three, four, five, six or seven variables that are chosen from the group consisting of platelets (PLQ) and prothrombin rate (TP); in the case where exactly three variables are measured, these three variables cannot be together platelets (PLQ), prothrombin rate (TP) and bilirubin; and, the three, four, five, six or seven variables chosen do not together comprise α-2 macroglobulin (A2M), hyaluronic acid (AH or hyaluronate) and tissue inhibitor of matrix 1 metalloproteinase (TIMP-1), b) collect at least one clinical variable that characterizes said subject and; For the diagnostic score of portal and septal fibrosis, stages a) and b) above are such that at least 4 variables are measured or collected, c) combine, in a logical or linear function, the following variables: α-2 macroglobulin ( A2M) and prothrombin rate (TP) and at least two variables chosen among platelets (PLQ), aspartate amino transferase (ASAT), urea, hyaluronic acid (AH) and age, in order to obtain a diagnostic result of portal fibrosis and septal; d) diagnose the presence and / or severity of said pathology and / or the efficacy of said treatment from the result obtained during the combination of step (c).

机译：诊断受试者的肝脏病理学，特别是肝纤维化的存在和/或严重性的方法，包括通过进行以下步骤来建立门静脉和间隔纤维化的至少一种非侵入性诊断评分：a）在所述受试者的样品，选自由α-2巨球蛋白（A2M），透明质酸（AH或透明质酸盐），载脂蛋白A1（ApoA1），III型原胶原的N末端前肽组成的组的三个，四个，五个，六个或七个变量（P3P），γ-谷氨酰转肽酶（GGT），胆红素，γ球蛋白（GLB），血小板（PLQ），凝血酶原率（TP），天冬氨酸氨基转移酶（ASAT），丙氨酸氨基转移酶（ALAT），尿素，钠（NA），血糖，甘油三酸酯，白蛋白（ALB），碱性磷酸酶（PAL），YKL-40（人软骨糖蛋白39），组织基质1金属蛋白酶抑制剂（TIMP-1），基质2金属蛋白酶（MMP-2），铁蛋白，一种至少三个，四个，五个，六个或七个变量c来自血小板（PLQ）和凝血酶原速率（TP）的软管;如果仅测量了三个变量，则这三个变量不能同时为血小板（PLQ），凝血酶原率（TP）和胆红素的总和。并且选择的三个，四个，五个，六个或七个变量不同时包含α-2巨球蛋白（A2M），透明质酸（AH或透明质酸盐）和基质1金属蛋白酶的组织抑制剂（TIMP-1），b）收集在至少一个表征所述受试者的临床变量，以及对于门静脉和间隔纤维化的诊断评分，上述阶段a）和b）使得至少要测量或收集4个变量，c）在逻辑或线性函数中结合以下变量：α-2巨球蛋白（A2M ）和凝血酶原率（TP）以及从血小板（PLQ），天冬氨酸氨基转移酶（ASAT），尿素，透明质酸（AH）和年龄中选择的至少两个变量，以获得门静脉纤维化和间隔的诊断结果; d）根据在步骤（c）的组合期间获得的结果，诊断所述病理的存在和/或严重性和/或所述治疗的功效。

著录项

公开/公告号ES2455229T3

专利类型
公开/公告日2014-04-15

原文格式PDF
申请/专利权人 UNIVERSITE DANGERS;CENTRE HOSPITALIER UNIVERSITAIRE DANGERS;
展开▼

申请/专利号ES20050771179T
发明设计人 CALES PAUL;
展开▼

申请日2005-05-13
分类号G01N33/68;C12Q1/34;C12Q1/37;C12Q1/48;G01N33/576;G06F19;
国家 ES
入库时间 2022-08-21 15:55:09

相似文献

专利
外文文献
中文文献